U.S. Markets closed

Wave Life Sciences Plunges on Clinical Trial Data Delay

Tony Owusu

shares were down more than 16% to $34.85 Wednesday after the biopharmaceutical company said it will delay the release of top-line data from the clinical trials of its Huntington's disease treatment candidate. "When we initiated these exciting clinical trials to explore the potential of an allele-selective approach to treating Huntington's disease, we set aggressive timelines for ourselves in recognition of the enormous need in the global Huntington's disease community. While we are disappointed that enrollment is not as fast as we anticipated, we are pleased that patient and physician interest in the trials remains high," said Dr. Michael Panzara, chief medical officer at Wave Life Sciences.